NORLETIMOL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H13NO
Molecular Weight	211.2591
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=CC=CC=C1\C=N\CC2=CC=CC=C2

InChI

InChIKey=LPSMMAHYAIVSQW-RVDMUPIBSA-N

InChI=1S/C14H13NO/c16-14-9-5-4-8-13(14)11-15-10-12-6-2-1-3-7-12/h1-9,11,16H,10H2/b15-11+

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3831573 | https://www.ncbi.nlm.nih.gov/pubmed/488132 | Elks, J. (2014) The Dictionary of Drugs: Chemical Data, page 888, retrieved from: https://books.google.ru/books?id=0vXTBwAAQBAJ

Norletimol is a Schiff base with promising anti-inflammatory properties. The time taken for elimination of 50% of the Norletimol dose in the urine was approximately five hours. As an antirheumatic agent it was tested in clinical trials in Iraq. It was used in progressive myopia in children.

Originator

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Rheumatoid arthritis 320 Sources: Elks, J. (2014) The Dictionary of Drugs: Chemical Data, page 888, retrieved from: https://books.google.ru/books?id=0vXTBwAAQBAJ	Primary		Phase II 1147	Unknown Approved Use Unknown
Progressive myopia 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3831573	Primary		Not Provided 511	Unknown Approved Use Unknown

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP19A1 429	P-gp 2052

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645840#sid=170466235	inconclusive [IC50 38.9018 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/743139#sid=144205392	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1645842#sid=170466235	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346984#sid=144205392	yes [IC50 14.1254 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 2052	substrate 4014 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1346987#sid=144205392	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/588834#sid=144205392

Sourcing

Vendor/Aggregator	ID	URL
Alfa Chemistry	886-08-8	https://www.alfa-chemistry.com/cas_886-08-8.htm
Aurora Fine Chemicals LLC	A18.003.657	http://online.aurorafinechemicals.com/info?ID=A18.003.657
ChemMol	99160535	http://www.chemmol.com/chemmol/99160535.html
Chemspace	CSSS00016271698	https://chem-space.com/CSSS00016271698
Debye Scientific	DS-002664	http://www.debyesci.com/cas_886-08-8.html
Lab Network	LN00403382	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00403382
mcule	MCULE-9890423190	https://mcule.com/MCULE-9890423190/
MolPort	MolPort-000-913-813	https://www.molport.com/shop/molecule-link/MolPort-000-913-813
Sigma-Aldrich	S645923_ALDRICH	https://www.sigmaaldrich.com/catalog/product/aldrich/s645923
Sinfoo Biotech	S050117	http://www.sinfoobiotech.com/product/1053515
Smolecule	S561802	https://www.smolecule.com/products/s561802
THE BioTek	bt-426742	https://www.thebiotek.com/product/others/bt-426742
Vitas-M Laboratory	STL363947	http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=STL363947&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink

PubMed

Title	Date	PubMed
Escape from a nonporous solid: mechanically coupled biconcave molecules.	2005-10-21	16173003
[Treatment of progressive myopia in children by saddamine and calcium iontophoresis and difrarel].	1985-08	3831573
The metabolism of salicylidene benzylamine, a pro-drug for salicylate, in rats and dogs.	1983-01	6858201
GLC determination of purity of Schiff bases bakrine and saddamine.	1979-03	423134
The metabolism of saddamine in man: the fate of the benzylamine moiety of saddamine.	1979	488132
Comparison of the major urinary metabolites of saddamine and aspirin using thin-layer chromatography.	1978-12-11	748364

Patents

Sample Use Guides

In Vivo Use Guide

Rat: 50, 100 and 300 mg/kg Dog: 44, 85 and 300 mg/kg

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

NSC-128931

Preferred Name

English

NORLETIMOL

Official Name

English

norletimol [INN]

Common Name

English

PHENOL, 2-((E)-((PHENYLMETHYL)IMINO)METHYL)-

Systematic Name

English

O-(N-BENZYLFORMIMIDOYL)PHENOL

Systematic Name

English

PHENOL, 2-(((PHENYLMETHYL)IMINO)METHYL)-, (E)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C308